Aurora Cannabis Gets a Buy Rating from Canaccord Genuity

By Carrie Williams

Today, an analyst has provided a rating update for the Materials sector company, Aurora Cannabis (TSXV: ACB). Analyst Neil Maruoka from Canaccord Genuity remains bullish on the stock and has a C$3.25 price target.

According to, Maruoka is a 1-star analyst with an average return of -1.8% and a 37.3% success rate. Maruoka covers the Healthcare sector, focusing on stocks such as Merus Labs International, Cardiome Pharma Corp, and Concordia Healthcare.

Aurora Cannabis has an analyst consensus of Moderate Buy, with a price target consensus of C$3.25.

The company has a one year high of C$3.95 and a one year low of C$0.40. Currently, Aurora Cannabis has an average volume of 3.06M.

Aurora Cannabis, Inc. operates as a licensed producer of medical marijuana in Canada. Its medical cannabis products include Borealis Blend, Odin, Odin 3, Peechee, Sentinel, Stokes, and Warwick 2. The company was founded by Terry Booth and Steve Dobler on December 21, 2006 and is headquartered in Vancouver, Canada.

The company’s shares closed on Thursday at $2.19.